What's in Yung Shin Pharm. Ind. Co., Ltd.'s pipeline?

Yung Shin Pharm. Ind. Co., Ltd. has 9 drugs in our index: 7 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Yung Shin Pharm. Ind. Co., Ltd.'s portfolio?

Top competitors by shared drug class: Asian Institute of Gastroenterology, India, Bayer, GlaxoSmithKline, Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva, Hospital Italiano de Buenos Aires.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/yung-shin-pharm-ind-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Yung Shin Pharm. Ind. Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yung Shin Pharm. Ind. Co., Ltd. pipeline: 7 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Mepem	Mepem	marketed			Other
Entigin Film Coated Tablet 0.5mg	Entigin Film Coated Tablet 0.5mg	marketed
Vaway	Vaway	marketed			Other
Esomelone	Esomelone	marketed			Other
valacyclovir hydrocholoride	valacyclovir hydrocholoride	marketed
Meropem	Meropem	marketed			Other
cefoperazone sodium and sulbactam sodium	cefoperazone sodium and sulbactam sodium	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; beta-lactamases	Infectious Disease

Therapeutic area mix

Other · 5
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Asian Institute of Gastroenterology, India · 1 shared drug class
Bayer · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva · 1 shared drug class
Hospital Italiano de Buenos Aires · 1 shared drug class
Imperial College London · 1 shared drug class
Kaizen Bioscience Co. · 1 shared drug class
Albany Medical College · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Yung Shin Pharm. Ind. Co., Ltd.:

Cite this brief

Drug Landscape (2026). Yung Shin Pharm. Ind. Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yung-shin-pharm-ind-co-ltd. Accessed 2026-05-17.